alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
### Ground-water resources of Orange and Ulster Counties, New York

By: Michael H. Frimpter

                            https://doi.org/10.3133/wsp1985

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (8015 pdf)                        
  - **Plate 2**                            (7781 pdf)                        
  - **Plate 3**                            (2603 pdf)                        
  - **Plate 4**                            (433 pdf) 
- Superseded Publications:
                                        Ground-water basic data for Orange and Ulster Counties, New York(1969)                                    

- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 1998 AND THE CONSOLIDATED STATEMENT OF
OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 1998 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                           8,142
<SECURITIES>                                     5,672
<RECEIVABLES>                                    2,857
<ALLOWANCES>                                         0
<INVENTORY>                                      7,412
<CURRENT-ASSETS>                                24,553
<PP&E>                                          23,593
<DEPRECIATION>                                (13,913)
<TOTAL-ASSETS>                                  44,356
<CURRENT-LIABILITIES>                           17,168
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            15
<OTHER-SE>                                      25,635
<TOTAL-LIABILITY-AND-EQUITY>                    44,356
<SALES>                                          2,493
<TOTAL-REVENUES>                                 2,588
<CGS>                                            1,233
<TOTAL-COSTS>                                    1,918
<OTHER-EXPENSES>                                 6,033
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   6
<INCOME-PRETAX>                                (4,965)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (4,965)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (4,965)
<EPS-PRIMARY>                                   (0.34)
<EPS-DILUTED>                                   (0.34)
        

</TABLE>
§ 26.37 Confidence building activities. ( a ) At the beginning of the transitional period, the Joint Sectoral Group will establish a joint confidence building program calculated to provide sufficient evidence of the capabilities of the designated conformity assessment bodies (CAB's) to perform quality system or product evaluations to the specifications of the parties.
( b ) The joint confidence building program should include the following actions and activities: ( 1 ) Seminars designed to inform the parties and CAB's about each party's regulatory system, procedures, and requirements;
( 2 ) Workshops designed to provide the parties with information regarding requirements and procedures for the designation and surveillance of CAB's;
( 3 ) Exchange of information about reports prepared during the transition period;
( 4 ) Joint training exercises; and
( 5 ) Observed inspections.
( c ) During the transition period, any significant problem that is identified with a CAB may be the subject of cooperative activities, as resources allow and as agreed to by the regulatory authorities, aimed at resolving the problem.
( d ) Both parties will exercise good faith efforts to complete the confidence building activities as expeditiously as possible to the extent that the resources of the parties allow.
( e ) Both the parties will each prepare annual progress reports which will describe the confidence building activities undertaken during each year of the transition period. The form and content of the reports will be determined by the parties through the Joint Sectoral Committee.
----

|   | (1) | In connection with the Annual Report of the Company on form 10-K for the twelve month period ended May 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities and Exchange Act of 1934; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company for the periods presented therein.. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By:                      | /s/ Daniel W. Dowe          |   |
|--------|--------------------------|-----------------------------|--------|
|   |                     | Daniel W. Dowe              |   |
|   |                     | Chief Executive Officer and |   |
|   |                     | Chief Financial Officer     |   |
|   |                     |                        |   |
|   | Date: September 14, 2010 |

----
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                         1389346
<SECURITIES>                                         0
<RECEIVABLES>                                   210603
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               1600363
<PP&E>                                        19041247
<DEPRECIATION>                                 5271057
<TOTAL-ASSETS>                                23392758
<CURRENT-LIABILITIES>                           468822
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    19170616
<TOTAL-LIABILITY-AND-EQUITY>                  23392758
<SALES>                                          75342
<TOTAL-REVENUES>                               1515155
<CGS>                                                0
<TOTAL-COSTS>                                   123525
<OTHER-EXPENSES>                                339789
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               74018
<INCOME-PRETAX>                                 977823
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             977823
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    977823
<EPS-PRIMARY>                                    16.49
<EPS-DILUTED>                                    16.49
        

</TABLE>
§ 216.23 Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. ( a ) The following bulk drug substances can be used in compounding under section 503A(b)(1)(A)(i)(III) of the Federal Food, Drug, and Cosmetic Act. ( 1 ) Brilliant Blue G, also known as Coomassie Brilliant Blue G-250.
( 2 ) Cantharidin (for topical use only).
( 3 ) Diphenylcyclopropenone (for topical use only).
( 4 ) N-acetyl-D-glucosamine (for topical use only).
( 5 ) Squaric acid dibutyl ester (for topical use only).
( 6 ) Thymol iodide (for topical use only).
( b ) After balancing the criteria set forth in paragraph (c) of this section, FDA has determined that the following bulk drug substances will not be included on the list of substances that can be used in compounding set forth in paragraph (a) of this section: ( 1 ) Oxitriptan.
( 2 ) Piracetam.
( 3 ) Silver Protein Mild.
( 4 ) Tranilast.
( c ) FDA will use the following criteria in evaluating substances considered for inclusion on the list set forth in paragraph (a) of this section: ( 1 ) The physical and chemical characterization of the substance;
( 2 ) Any safety issues raised by the use of the substance in compounded drug products;
( 3 ) The available evidence of the effectiveness or lack of effectiveness of a drug product compounded with the substance, if any such evidence exists; and
( 4 ) Historical use of the substance in compounded drug products, including information about the medical condition(s) the substance has been used to treat and any references in peer-reviewed medical literature.
( d ) Based on evidence currently available, there are inadequate data to demonstrate the safety or efficacy of any drug product compounded using any of the drug substances listed in paragraph (a) of this section, or to establish general recognition of the safety or effectiveness of any such drug product. Any person who represents that a compounded drug made with a bulk drug substance that appears on this list is FDA approved, or otherwise endorsed by FDA generally or for a particular indication, will cause the drug to be misbranded under section 502(a) and/or 502(bb) of the Federal Food, Drug, and Cosmetic Act.
[84 FR 4710, Feb. 19, 2019]
<PAGE>
 
                                                                    EXHIBIT 21.1
                                                                                

                   Subsidiaries of Astea International Inc.
                   ----------------------------------------
                                        
                               December 31, 1998



Company Name                                    Jurisdiction of Organization
------------                                    ----------------------------

Astea FSC                                       Barbados
Astea GmbH                                      Germany
Astea International (AUST) PTY LTD              New South Wales
Astea Israel Ltd.                               Israel
Astea Service and Distribution Systems Ltd.     England
Astea Sarl                                      France
Astea Service and Distribution Systems B.V.     Netherlands
Astea Technology Inc.                           Delaware
Group Technologies, Inc.                        Delaware
Network Data, Inc.                              Delaware
Virtual Service Corporation                     Delaware

                                      56
| (logo) WELLS

           FARGO

  | Commercial Mortgage Servicing

D1086-120, 12th Floor

550 South Tryon Street

Charlotte, NC 28202

1-800-326-1334

  |
|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|

 

 

ANNUAL STATEMENT OF COMPLIANCE

 

Reference is hereby made to that certain Pooling and Servicing Agreement dated as of March 1, 2013, by and among DEUTSCHE MORTGAGE & ASSET RECEIVING CORPORATION, as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Special Servicer, U.S. BANK NATIONAL ASSOCIATION, as Trustee, and DEUTSCHE BANK TRUST COMPANY AMERICAS, as Certificate Administrator, Paying Agent and Custodian, and PARK BRIDGE LENDER SERVICES LLC as Operating Advisor with respect to Commercial Mortgage Pass-Through Certificates, Series COMM 2013-CCRE6 (the "Agreement"). Capitalized terms used herein not otherwise defined shall have the meanings assigned in the Agreement.

 

Pursuant to Section 10.11 of this Agreement, I, Daniel Bober, Executive Vice President of

Commercial Mortgage Services do hereby certify that:

 

 

1.        A review of the activities of the Master Servicer during the period from January 1, 2014 through December 31, 2014 (the “Reporting Period”), and of its performance per the Agreement during such period has been made under my supervision, and

 

2.        To the best of my knowledge, based on such review, the Master Servicer has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.

 

 

 

IN WITNESS WHEREOF, the undersigned has executed this Certificate as of the 6th day of March 2015.

 

 

 

/s/ Daniel Bober 

Daniel Bober

Executive Vice President

Wells Fargo Bank

 

 

 
| Wells Fargo Bank, N.A. | (logo) Together we’ll go far |
|------------------------|------------------------------------|
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAY-31-1997
<PERIOD-END>                               AUG-30-1997
<CASH>                                         526,832
<SECURITIES>                                         0
<RECEIVABLES>                                1,533,144
<ALLOWANCES>                                         0
<INVENTORY>                                  1,194,698
<CURRENT-ASSETS>                             3,811,962
<PP&E>                                       4,574,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               9,115,130
<CURRENT-LIABILITIES>                        2,749,568
<BONDS>                                      2,021,244
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        15,444
<OTHER-SE>                                   2,868,360
<TOTAL-LIABILITY-AND-EQUITY>                 9,115,130
<SALES>                                      4,676,967
<TOTAL-REVENUES>                             4,676,967
<CGS>                                        3,668,561
<TOTAL-COSTS>                                4,863,480
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              43,851
<INCOME-PRETAX>                              (218,724)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (218,724)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (218,724)
<EPS-PRIMARY>                                   (0.14)
<EPS-DILUTED>                                   (0.14)
        

</TABLE>
Exhibit 15.1





CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM








To the Board of Directors


Ellomay Capital Ltd.:





We consent to the incorporation by reference in the registration statements (Nos. 333-187533, 333-102288 and 333-92491) on Form S-8 and (Nos. 333- 199696 and 333-144171) on Form F-3 of Ellomay Capital Ltd. of our report dated April 30, 2015, with respect to the consolidated statements of financial position of Ellomay Capital Ltd. as of December 31, 2014 and 2013 and the related consolidated statements of profit or loss and other comprehensive income (loss), changes in equity and cash flows for each of the years in the three-year period ended December 31, 2014, which report appears in the December 31, 2014 annual report on Form 20-F of Ellomay Capital Ltd.





/s/ Somekh Chaikin
 Somekh Chaikin
 
 Certified Public Accountants (Isr).
 Member firm of KPMG International
 
 Tel-Aviv, Israel
 
 April 30, 2015
EXHIBIT 32
----------




                             CERTIFICATIONS OF
            CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                    PURSUANT TO 18 U.S.C. SECTION 1350,
                 AS ADOPTED PURSUANT TO SECTION 906 OF THE
                        SARBANES-OXLEY ACT OF 2002
            ---------------------------------------------------



      The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2009,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

      Each of the undersigned certifies that the foregoing Report on
Form 10-Q/A fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q/A fairly presents, in all material respects, the
financial condition and results of operations of ALP Liquidating Trust.




                                          /s/   Gary Nickele
                                          ------------------------------
                                          Gary Nickele
                                          Chief Executive Officer




                                          /s/   Gailen J. Hull
                                          ------------------------------
                                          Gailen J. Hull
                                          Chief Financial Officer and
                                          Principal Accounting Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-K
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               MAR-31-1999
<CASH>                                          39,303
<SECURITIES>                                         0
<RECEIVABLES>                                1,143,919
<ALLOWANCES>                                         0
<INVENTORY>                                  1,009,754
<CURRENT-ASSETS>                             2,290,623
<PP&E>                                         907,533
<DEPRECIATION>                                 243,777
<TOTAL-ASSETS>                               3,206,480
<CURRENT-LIABILITIES>                        1,363,776
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         6,410
<OTHER-SE>                                  10,309,361
<TOTAL-LIABILITY-AND-EQUITY>                 3,206,480
<SALES>                                      7,807,291
<TOTAL-REVENUES>                             7,807,291
<CGS>                                        5,750,127
<TOTAL-COSTS>                                2,377,592
<OTHER-EXPENSES>                              (74,594)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             280,456
<INCOME-PRETAX>                              (526,290)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (526,290)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (526,290)
<EPS-BASIC>                                     (0.09)
<EPS-DILUTED>                                   (0.09)


</TABLE>
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.70 Calcium labeling. ( a ) The labeling of over-the-counter (OTC) drug products intended for oral ingestion shall contain the calcium content per dosage unit (e.g., tablet, teaspoonful) if the calcium content of a single maximum recommended dose of the product (which may be one or more dosage units) is 20 milligrams or more. OTC drug products intended for oral ingestion include gum and lozenge dosage forms, but do not include dentifrices, mouthwashes, or mouth rinses.
( b ) The calcium content shall be expressed in milligrams or grams per dosage unit and shall include the total amount of calcium regardless of the source, i.e., from both active and inactive ingredients. If the dosage unit contains less than 1 gram of calcium, milligrams should be used. The calcium content per dosage unit shall be rounded-off to the nearest 5 milligrams (or nearest tenth of a gram if over 1 gram). The calcium content per dosage unit shall follow the heading “Other information” as stated in § 201.66(c)(7).
( c ) The labeling of OTC drug products intended for oral ingestion shall contain the following statement under the heading “Warning” (or “Warnings” if it appears with additional warning statements) if the amount of calcium present in the labeled maximum daily dose of the product is more than 3.2 grams: “Ask a doctor before use if you have [in bold type] [bullet][1] kidney stones [bullet] a calcium-restricted diet”. The warnings in §§ 201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical order, e.g., a calcium or sodium restricted diet.
( d ) Any product subject to this paragraph that is not labeled as required by this paragraph and that is initially introduced or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n) and 502(a) and (f) of the Federal Food, Drug, and Cosmetic Act. ( 1 ) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.
( 2 ) September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.
[69 FR 13733, Mar. 24, 2004] Footnotes -
201.70
[1] See § 201.66(b)(4) of this chapter for definition of bullet symbol.